Bio Pharma Dive
DECEMBER 14, 2023
According to Apellis executives, reviewers in Europe are skeptical of the benefits of its geographic atrophy medicine, Syfovre, and appear poised to recommend against approval at a meeting next month.
Pharmaceutical Technology
DECEMBER 14, 2023
Acadia received two patent rulings that strengthen Nuplazid’s patent position and protect the drug into 2038.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
DECEMBER 14, 2023
Shares climbed by double digits after new evidence led to speculation among analysts that Moderna and partner Merck could seek an approval before completing Phase 3 testing.
Pharma Times
DECEMBER 14, 2023
The collaboration aims to develop biomarker-based diagnostics for the condition - News - PharmaTimes
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
DECEMBER 14, 2023
The deal, struck after Editas was awarded ownership of a key patent for the landmark gene editing technology, could be the first of many like it.
Fierce Pharma
DECEMBER 14, 2023
Pfizer’s $43 billion acquisition of Seagen is in the books, the company said on Thursda | It’s a done deal. Pfizer’s $43 billion acquisition of Seagen is in the books, as it becomes the largest M&A transaction in the biopharma industry since AbbVie snatched up Allergan for $63 billion in 2019. The buyout of the antibody-drug conjugate specialist has doubled Pfizer’s pipeline to 60 programs.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Times
DECEMBER 14, 2023
The free programme will be offered to those who are affected by the condition - News - PharmaTimes
Pharmaceutical Technology
DECEMBER 14, 2023
A Phase II clinical trial treating 160 acute kidney injury patients with MTX652 is expected to be initiated in Q1 2024.
Fierce Pharma
DECEMBER 14, 2023
Despite the high list price of Lyfgenia, bluebird has signed a large reimbursement deal for the sickle cell disease (SCD) gene therapy less than a week after its
Pharmaceutical Technology
DECEMBER 14, 2023
Novo Nordisk will pay $92.5m in one-time cash payment to Alkermes, and the deal is expected to close in mid-2024.
Pharmaceutical Technology
DECEMBER 14, 2023
Experts discussed the potential impacts of climate change on the pharma supply chain and how companies can prepare for them.
pharmaphorum
DECEMBER 14, 2023
AI drug discovery: Where we are and where we’re going Mike.
Pharmaceutical Technology
DECEMBER 14, 2023
The payment, which encompasses newly approved Casgevy, is the latest deal in a long line of CRISPR licensing twists and turns.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
DECEMBER 14, 2023
White House says 48 drugs are heading for Medicare rebates Phil.
Pharmaceutical Technology
DECEMBER 14, 2023
At ISPOR 2023, where GlobalData had the opportunity to share some of our key insights across a variety of subject matters.
Fierce Pharma
DECEMBER 14, 2023
While existing neuroblastoma treatments can help patients achieve remission, sustaining that remission has proven tricky. But now, patients and doctors have a new oral option. | The U.S. FDA has approved US WorldMeds’ Iwilfin—also known as eflornithine—as a new oral maintenance therapy for high-risk neuroblastoma. The drug, cleared in 192 mg tablets, is indicated to cut the risk of relapse in kids and adults with high-risk neuroblastoma who’ve had at least a partial response to prior treatment.
Pharmaceutical Technology
DECEMBER 14, 2023
In this article, we’ll explore the patient communication risks that now confront life science organisations and provide insights into how to navigate them effectively.
pharmaphorum
DECEMBER 14, 2023
Hemgenix first drug to clear France’s ‘direct access’ route Phil.
Pharmaceutical Technology
DECEMBER 14, 2023
Abbisko Therapeutics has received fast track designation from the US FDA for pimicotinib to treat tenosynovial giant cell tumour (TGCT).
pharmaphorum
DECEMBER 14, 2023
FDA starts speedy review of Amgen’s lung cancer BiTE therapy Phil.
Pharmaceutical Technology
DECEMBER 14, 2023
The US FDA has granted fast track designation for Kyverna Therapeutics’ CAR T-cell therapy KYV-101 to treat myasthenia gravis (MG).
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
DECEMBER 14, 2023
Twin Health raises $50m, and other digital health financings Phil.
Pharmaceutical Technology
DECEMBER 14, 2023
Accord Healthcare is a Category Award Winner in four areas in the 2023 Pharmaceutical Technology Excellence Awards
pharmaphorum
DECEMBER 14, 2023
MindMed says LSD-based therapy effective in anxiety Phil.
Pharmaceutical Technology
DECEMBER 14, 2023
Amgen has received US FDA priority review for its biologics licence application for tarlatamab to treat advanced small-cell lung cancer.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Commerce
DECEMBER 14, 2023
Partner for Archbow Consulting discusses the conference, the IRA, and specifics of PAP business rules
BioSpace
DECEMBER 14, 2023
The regulator placed the clinical hold on the Chinese biotech’s trio of CAR-T cell therapy candidates after an inspection of its Durham, North Carolina manufacturing facility.
Pharmaceutical Commerce
DECEMBER 14, 2023
Bill Trombetta, PhD, discusses successfully navigating what he calls “the coming perfect storm” in healthcare.
Outsourcing Pharma
DECEMBER 14, 2023
Celadon Pharmaceuticals has today (December 14) announced its first supply of it pharmaceutical-grade breakthrough cannabis-based medicine.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
321 
Let's personalize your content